infect
reignit
interest
antibodybas
therapeut
sinc
product
process
monoclon
antibodi
prolong
costli
altern
treatment
investig
produc
purifi
equin
antisera
hors
hyperimmun
ebov
viruslik
particl
test
postexposur
efficaci
antisera
mous
model
infect
balbc
mice
given
mg
purifi
equin
antisera
per
anim
minut
day
postinfect
dpi
anim
surviv
decreas
possibl
serum
sick
equin
antisera
digest
pepsin
gener
f
fragment
vitro
neutral
activ
compar
whole
immunoglobulin
full
protect
achiev
treatment
initi
dpi
suboptim
protect
observ
minut
dpi
group
demonstr
addit
viru
neutral
fcdepend
antibodi
mechan
may
also
contribut
surviv
guinea
pig
given
mg
antisera
f
start
dpi
also
fulli
protect
ebov
infect
result
justifi
futur
efficaci
studi
purifi
equin
product
nhp
ebola
viru
ebov
pathogen
filovirida
famili
capabl
caus
sever
hemorrhag
fever
human
nonhuman
primat
past
outbreak
ebov
diseas
evd
sporad
unpredict
local
remot
region
central
africa
death
toll
reach
ebov
one
lethal
virus
known
human
licens
prophylact
therapeut
still
remain
unavail
clinic
set
current
littl
done
infect
patient
outsid
support
care
includ
fluid
replenish
administr
antivir
manag
secondari
symptom
combin
reason
mean
high
person
risk
involv
work
ebov
laboratori
set
classifi
biosafeti
level
agent
spring
new
ebov
variant
emerg
west
african
nation
guinea
area
viru
previous
report
outbreak
soon
spread
neighbour
sierra
leon
liberia
occasion
case
export
countri
travel
countri
locat
africa
europ
north
america
record
ebov
case
import
travel
repatri
infect
citizen
middecemb
fatal
infect
largest
evd
outbreak
histori
although
outbreak
larg
control
report
case
sinc
week
novemb
th
viru
shown
peak
outbreak
extrem
resist
tradit
contain
method
design
curb
ebov
transmiss
passiv
immunotherapi
sera
anim
origin
use
year
treat
bacteri
viral
infect
envenom
drug
intox
report
demonstr
passiv
transfer
igg
nonhuman
primat
nhp
survivor
ebov
diseas
naiv
nhp
suffici
confer
postexposur
protect
ebov
challeng
anim
build
find
cocktail
monoclon
antibodi
mab
rais
ebov
glycoprotein
gp
soon
shown
afterward
effect
treatment
ebov
diseas
culmin
develop
zmapp
tm
combin
three
mab
produc
genet
modifi
tobacco
plant
shown
revers
advanc
ebov
diseas
experimentallyinfect
nhp
may
provid
surviv
benefit
administ
ebovinfect
patient
second
antibodi
cocktail
base
zmapp
tm
produc
modifi
cho
cell
later
shown
similar
efficaci
zmapp
tm
nhp
therefor
passiv
immunotherapi
extrem
promis
approach
control
ebov
diseas
due
eas
manag
high
antibodi
yield
low
risk
human
contamin
viru
adventiti
agent
hors
commonli
use
anim
speci
product
hyperimmun
sera
immun
standard
perform
optim
condit
personnel
anim
passiv
immunotherapi
still
commonli
use
countri
still
resourcepoor
medic
treatment
immun
globulin
rabi
viru
clostridium
tetani
infect
remain
frequent
africa
asia
latin
america
lower
manufactur
cost
hyperimmun
equin
antisera
therefor
repres
attract
altern
avenu
treatment
especi
develop
thirdworld
countri
compar
costli
product
process
ebov
gpspecif
mab
investig
first
prepar
purifi
antiebov
antisera
via
immun
hors
ebov
envelop
viruslik
particl
evlp
consist
ebov
viral
protein
gp
equin
antisera
test
vitro
use
neutral
assay
recombin
ebov
express
egfp
ebovegfp
well
vivo
lethal
challeng
mouseadapt
ebov
maebov
immunocompet
balbc
mice
investig
whether
ebov
infect
control
viru
neutral
alon
prevent
possibl
induct
serum
sick
human
would
administ
antisera
postexposur
efficaci
f
immunoglobulin
treat
pepsin
remov
fc
region
antibodi
also
investig
sidebysid
equin
antisera
experi
potenti
altern
treatment
guinea
pig
use
confirm
efficaci
result
mous
studi
due
statu
higher
phylogen
speci
close
model
hallmark
evd
human
addit
prior
efficaci
studi
equin
antisera
f
evalu
safeti
peke
union
medic
colleg
center
new
drug
safeti
evalu
chines
academi
medic
scienc
certifi
food
drug
agenc
peopl
republ
china
equinederiv
product
found
meet
safeti
standard
clinic
use
china
immun
hors
product
equin
antibodi
product
hors
immun
evlp
produc
infect
cell
filament
evlp
observ
electron
microscop
supplementari
figur
confirm
morpholog
similar
ebov
immunoblot
infect
cell
lysat
demonstr
evlp
contain
ebov
gp
supplementari
figur
three
hors
immun
intramuscularli
im
inject
evlp
week
hyperimmun
sera
collect
anim
specifi
timepoint
fig
determin
serum
titer
neutral
assay
recombin
viru
pseudotyp
ebov
gp
pseudotypedviru
use
studi
confirm
vitro
efficaci
antisera
prepar
biosafeti
level
condit
subsequ
studi
laboratori
neutral
serum
titer
detect
immun
week
increas
immun
week
fig
serum
neutral
antibodi
titer
two
hors
seven
immun
third
anim
equin
antisera
purifi
ammonium
sulphatebas
precipit
digest
pepsin
concentr
uml
min
purifi
gener
f
fragment
puriti
antisera
f
prepar
determin
sdspage
follow
thin
layer
chromatographi
determin
respect
fig
approxim
ml
purifi
antisera
could
obtain
hors
collect
stock
concentr
mgml
collect
perform
hors
therefor
hyperimmun
hors
yield
g
purifi
antisera
vitro
character
equin
antisera
f
ab
equin
antisera
f
product
first
character
laboratori
gener
ebovegfp
potenti
neutral
ebov
equin
antisera
f
found
possess
level
similar
neutral
activ
half
effect
maxim
concentr
ec
product
respect
fig
moreov
neutral
activ
equin
antisera
f
complet
concentr
scientif
report
doi
indic
two
product
indistinguish
term
neutral
high
concentr
ebovspecif
igg
equin
antisera
prepar
also
determin
elisa
serial
neutral
activ
equin
antisera
f
ebovegfp
compar
differ
concentr
xaxi
total
fluoresc
infect
cell
dpi
shown
percentag
fluoresc
observ
pb
control
set
yaxi
sampl
process
triplic
error
bar
indic
standard
error
data
shown
figur
repres
three
independ
neutral
studi
f
antisera
dilut
stock
antisera
concentr
mgml
assay
triplic
three
independ
experi
titer
determin
endpoint
dilut
first
assess
guinea
pig
found
hour
day
respect
supplementari
tabl
protect
efficaci
equin
antisera
f
assess
three
experi
balbc
mice
first
experi
compar
efficaci
antisera
f
treatment
sidebysid
group
mice
given
intraperiton
ip
inject
f
per
dose
twice
daili
day
bid
start
either
day
postinfect
dpi
uniformli
lethal
dose
maebov
comparison
group
mice
administ
ip
inject
equin
igg
per
dose
qd
either
dpi
control
mice
given
equal
volum
pb
place
treatment
qd
dpi
pb
use
instead
nonspecif
immunoglobulin
f
previou
studi
involv
passiv
transfer
nonspecif
antisera
mice
nhp
result
protect
thu
surviv
due
nonspecif
effect
serum
protein
consid
unlik
control
mice
lost
approxim
bodi
weight
cours
experi
none
surviv
mean
time
death
mtd
dpi
five
eight
mice
given
f
start
dpi
surviv
pvalu
compar
pb
group
averag
weight
loss
mtd
dpi
howev
none
mice
given
f
start
dpi
surviv
challeng
pvalu
compar
pb
group
averag
weight
loss
mtd
dpi
fig
b
five
eight
mice
given
antisera
dpi
surviv
pvalu
compar
pb
group
averag
weight
loss
mtd
dpi
fig
three
eight
mice
given
antisera
dpi
surviv
pvalu
compar
pb
group
averag
weight
loss
mtd
dpi
fig
compar
group
equal
treatment
time
statist
differ
f
dpi
pvalu
respect
howev
given
multipl
administr
f
requir
achiev
similar
protect
level
demonstr
singl
inject
antisera
result
suggest
equin
antisera
superior
product
f
term
efficaci
possibl
due
longer
vivo
halflif
equin
antisera
sinc
f
appear
promis
earli
maebov
infect
dosag
treatment
increas
second
experi
group
mice
given
ip
inject
f
mg
per
dose
twice
daili
day
bid
start
either
minut
dpi
maebov
control
mice
treat
pb
qd
dpi
control
mice
lost
approxim
bodi
weight
cours
experi
none
surviv
mtd
dpi
partial
surviv
observ
treatment
began
minut
challeng
four
nine
mice
mg
group
surviv
pvalu
compar
pb
group
averag
weight
loss
mtd
dpi
wherea
four
ten
mice
mg
group
surviv
pvalu
compar
pb
group
averag
weight
loss
mtd
dpi
fig
b
contrast
mice
surviv
treatment
initi
dpi
neglig
weight
loss
less
observ
mg
group
pvalu
compar
pb
group
indic
protect
complet
result
indic
f
contribut
protect
maebov
within
certain
timefram
challeng
efficaci
equin
antisera
higher
dose
investig
third
experi
group
mice
given
ip
inject
antisera
mg
per
dose
qd
minut
dpi
maebov
control
mice
treat
pb
qd
dpi
control
mice
lost
approxim
bodi
weight
cours
experi
none
surviv
mtd
dpi
mice
treat
antisera
minut
dpi
surviv
neglig
weight
loss
pvalu
compar
pb
group
nine
ten
mice
treat
antisera
dpi
also
surviv
challeng
pvalu
compar
pb
group
lone
nonsurvivor
die
dpi
averag
peak
weight
loss
determin
within
treatment
group
fig
b
result
indic
equin
antisera
compar
f
abl
offer
greater
contribut
protect
maebov
mous
model
due
need
fewer
administr
achiev
similar
level
protect
guinea
pig
use
confirm
protect
effect
antisera
f
higher
phylogen
speci
ebov
challeng
sinc
anim
better
mimic
hallmark
human
ebov
infect
coagul
abnorm
group
anim
given
singl
ip
inject
antisera
qd
start
dpi
gaebov
twicedaili
ip
inject
f
three
day
bid
start
dpi
inject
dose
contain
mg
antisera
f
group
five
control
anim
given
singl
inject
pb
dpi
control
guinea
pig
lost
approxim
bodi
weight
cours
experi
none
surviv
mtd
dpi
guinea
pig
given
antisera
dpi
surviv
pvalu
group
compar
pb
group
clinic
sign
diseas
signific
weight
loss
fig
b
addit
anim
given
f
start
dpi
surviv
gaebov
challeng
pvalu
group
compar
pb
group
without
sign
diseas
signific
weight
loss
fig
b
dispar
efficaci
f
mice
guinea
pig
may
attribut
much
higher
dosag
f
administ
per
weight
f
dose
guinea
pig
higher
given
mice
guinea
pig
use
experi
time
bigger
mice
weight
lack
laboratori
global
train
personnel
well
rigor
work
high
biocontain
condit
sever
hamper
basic
research
ebov
lead
dearth
vaccin
therapeut
use
human
weak
expos
ebov
crise
highlight
valu
need
basic
translat
scienc
occur
prior
impend
threat
effort
save
live
sever
experiment
candid
treatment
test
efficaci
mice
nhp
addit
approv
nearlyapprov
drug
develop
unrel
pathogen
expedit
use
human
compassion
circumst
vari
degre
success
antibodybas
treatment
appear
hold
promis
clinic
thu
investig
use
human
passiv
immunotherapi
ebov
tri
past
toward
end
ebov
outbreak
kikwit
present
democrat
republ
congo
passiv
transfer
whole
blood
ebov
survivor
patient
result
surviv
seven
eight
recipi
howev
safeti
concern
blood
transfus
spread
bloodborn
diseas
allerg
reaction
concern
inefficaci
mean
approach
controversi
like
use
unless
better
altern
unavail
russian
investig
prepar
hyperimmun
antisera
hors
vaccin
inactiv
ebov
shown
effect
administ
dose
mgkg
baboon
surviv
survivor
given
hour
challeng
survivor
given
immedi
challeng
although
baboon
known
resist
ebov
infect
compar
nhp
speci
surviv
benefit
equin
antisera
limit
delay
onset
viremia
clinic
symptom
test
cynomolgu
macaqu
immedi
challeng
dose
mg
anim
weigh
kg
compar
success
passiv
immunotherapi
studi
purifi
igg
nhp
mgkg
well
zmapp
mgkg
dosag
cynomolgu
macaqu
experi
like
low
time
use
equin
antisera
emerg
postexposur
treatment
ebov
approv
russia
sever
investig
accident
expos
viru
administ
treatment
although
clear
actual
infect
result
studi
show
equin
antisera
f
prepar
rapidli
produc
larg
quantiti
lower
cost
compar
mab
effect
postexposur
treatment
maebov
challeng
mice
gaebov
infect
guinea
pig
f
develop
studi
due
past
document
issu
antisera
administr
equin
botulinum
toxin
antisnak
venom
antisera
shown
produc
serum
sick
high
dose
howev
mice
given
singl
dose
antisera
demonstr
complet
protect
greater
period
time
compar
multipl
inject
f
suggest
f
shorter
halflif
compar
igg
confirm
studi
andor
viru
neutral
play
partial
role
surviv
ebov
observ
administ
f
dpi
efficaci
treatment
given
minut
postexposur
fig
also
observ
past
studi
therapeut
ebov
gpspecif
monoclon
antibodi
suggest
viru
neutral
may
play
bigger
role
protect
later
timepoint
ebov
challeng
regard
neutral
past
report
shown
elev
antisera
level
nhp
vaccin
ebov
correl
surviv
level
specif
neutral
antibodi
possibl
explan
mab
origin
select
abil
neutral
ebov
fail
protect
nhp
given
dose
mgkg
start
day
challeng
suggest
futur
screen
potenti
efficaci
antibodi
ebov
base
sole
abil
antibodi
neutral
viru
fcdepend
antibodi
function
includ
antibodi
depend
cellular
cytotox
complementdepend
cytotox
neonat
fragment
crystalliz
receptor
fcr
mediat
crosspresent
like
play
role
protect
instanc
studi
mice
yellow
fever
viru
west
nile
viru
infect
shown
protect
mechan
monoclon
antibodi
depend
fcr
furthermor
complement
compon
previous
shown
influenza
viru
west
nile
viru
infect
directli
enhanc
neutral
activ
antibodi
mechan
mutual
exclus
determin
rel
import
propos
mechan
efficaci
surviv
yield
insight
specif
mechan
antibodi
help
protect
ebov
diseas
furthermor
find
studi
justifi
test
equin
igg
higher
phylogen
speci
ebov
nhp
may
result
develop
safe
econom
method
product
effect
ebov
therapeut
ethic
statement
mice
anim
balbc
mice
hartley
guinea
pig
purchas
commerci
supplier
charl
river
anim
kept
steril
autoclav
cage
provid
steril
food
water
ad
libitum
anim
also
provid
red
plastic
shelter
insid
cage
ad
sourc
stimul
hors
purchas
commerci
supplier
red
hill
militari
hors
farm
provid
food
water
ad
libitum
sequenc
ebov
gp
length
bp
respect
deriv
genbank
zair
ebolaviru
strain
zair
complet
genom
genbank
access
gp
gene
clone
vector
name
pucgp
insert
pfastbac
dual
vector
life
technolog
polyhedrin
promot
promot
respect
result
plasmid
pfastbac
purifi
plasmid
transform
bac
e
coli
life
technolog
transposit
bacmid
cellfect
ii
reagent
life
technolog
use
accord
manufactur
instruct
gener
recombin
baculovirus
coexpress
ebola
gp
evlp
product
inspect
produc
evlp
cell
infect
multipl
infect
moi
incub
day
cultur
supernat
harvest
centrifug
g
min
remov
cell
pellet
ultracentrifug
g
min
pellet
resuspend
pb
purifi
discontinu
sucros
gradient
g
min
evlp
band
obtain
densiti
rang
collect
wash
resuspend
pb
immunoblot
evlp
control
sampl
cell
cultur
supernat
separ
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
denatur
condit
transfer
onto
polyvinyliden
fluorid
pvdf
membran
whatman
kent
uk
probe
mous
antiebov
gp
polyclon
antibodi
prokaryot
express
gp
protein
immun
mice
mous
antiebov
monoclon
antibodi
abcam
dilut
overnight
sampl
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
secondari
antibodi
dilut
millipor
boston
usa
min
pvdf
membran
color
chemiluminesc
solut
pierc
biotechnolog
rockford
il
usa
electron
microscopi
evlp
appli
onto
carbonco
formvar
grid
immedi
stain
phosphotungst
acid
observ
transmiss
electron
microscop
hors
immun
hors
n
vaccin
intramuscularli
subcutan
multipoint
inject
either
mg
evlp
emulsifi
freund
complet
adjuvantfreund
incomplet
adjuv
week
time
blood
sampl
collect
jugular
vein
week
prior
first
immun
week
immun
sera
store
analysi
fragment
purif
equin
antibodi
product
equin
antisera
f
produc
changchun
institut
biolog
product
co
ltd
use
largescal
current
good
manufactur
practic
compat
equin
antiserum
manufactur
platform
equin
antisera
f
prepar
character
accord
guidelin
set
forth
chines
pharmacopoeia
edit
includ
appear
color
visibl
foreign
matter
ph
valu
f
immunoglobulin
content
steril
equin
antisera
blood
taken
jugular
vein
immun
hors
sera
separ
h
later
hors
sera
dilut
pb
centrifug
rpm
min
supernat
subject
filtrat
filter
antisera
purifi
ammonium
sulphat
precipit
follow
salt
column
store
nacl
solut
f
hors
sera
dilut
ph
adjust
use
hcl
antisera
subject
shock
digest
min
pepsin
naoh
ad
termin
digest
digest
product
subject
salt
column
purif
follow
protein
column
flowthrough
fluid
harvest
subject
ultrafiltr
remov
pepsin
small
molecular
protein
f
store
nacl
solut
sdspage
thin
layer
chromatographi
purifi
equin
antisera
f
sampl
mix
nonreduc
without
mercaptoethanol
protein
sampl
buffer
heat
min
subject
sdspage
gel
stain
h
destain
h
target
fraction
gel
examin
thin
layer
chromatographi
scanner
shimadzu
transmiss
zigzag
scan
dual
wavelength
swing
width
mm
delta
mm
determin
puriti
equin
antisera
f
elisa
ebov
gp
express
e
coli
dilut
bicarbon
buffer
ph
final
concentr
coat
elisa
plate
overnight
c
block
angiotensin
convert
enzym
ace
buffer
biorad
california
usa
h
plate
incub
serial
dilut
stock
equin
antisera
triplic
h
wash
hrpconjug
goat
antihors
igg
comwin
biotech
co
ltd
beij
china
dilut
tween
ad
well
incub
min
wash
substrat
tetramethylbenzidin
tmb
sigma
ad
incub
room
temperatur
min
reaction
stop
ad
h
absorb
measur
nm
dilut
consid
posit
absorb
read
least
twice
neg
control
pb
dilut
igg
endpoint
titer
calcul
highest
dilut
still
show
posit
result
assay
perform
independ
three
time
halflif
studi
guinea
pig
group
guinea
pig
administ
ip
inject
ml
purifi
equin
antisera
neutral
titer
f
neutral
titer
blood
sampl
collect
h
postinject
sera
use
determin
neutral
titer
recombin
viru
pseudotyp
ebov
gp
time
rang
postinfect
titer
decreas
consid
halflif
sampl
perform
triplic
determin
protect
efficaci
equin
antisera
balbc
mice
week
old
femal
weigh
g
randomli
assign
group
mice
anim
challeng
intraperiton
ip
dose
ld
mouseadapt
ebov
maebov
usamriidbalbclab
dmem
treatment
given
ip
qd
day
postinfect
dpi
mg
equin
antiebov
antisera
per
mous
subsequ
experi
given
ip
minut
dpi
mg
equin
antiebov
antisera
per
mous
control
group
given
volum
pb
mock
treatment
anim
monitor
sign
diseas
surviv
weight
chang
day
surviv
monitor
addit
day
femal
strain
hartley
guinea
pig
week
old
weigh
g
randomli
assign
group
anim
anim
challeng
ip
ld
guinea
pigadapt
ebov
gaebov
ml
dmem
treatment
given
ip
qd
dpi
mg
equin
antiebov
igg
per
anim
control
group
guinea
pig
given
volum
pb
mock
treatment
anim
monitor
sign
diseas
surviv
weight
chang
day
surviv
monitor
addit
day
determin
protect
efficaci
f
balbc
mice
week
old
femal
weigh
g
randomli
assign
group
mice
mice
challeng
ip
dose
maebov
dmem
treatment
given
ip
dpi
f
per
mous
subsequ
experi
given
ip
minut
dpi
either
mg
mg
f
per
mous
treatment
given
via
ip
twice
day
day
bid
control
group
given
volum
pb
mock
treatment
anim
monitor
sign
diseas
surviv
weight
chang
day
surviv
monitor
addit
day
femal
strain
hartley
guinea
pig
week
old
randomli
assign
group
anim
anim
challeng
ip
ld
guinea
pigadapt
ebov
ml
dmem
treatment
given
ip
dpi
mg
f
per
anim
treatment
given
via
ip
twice
day
day
bid
control
group
guinea
pig
given
volum
pb
mock
treatment
anim
monitor
sign
diseas
surviv
weight
chang
day
surviv
monitor
addit
day
pseudotyp
viru
neutral
assay
titer
equin
antisera
f
hors
test
neutral
assay
cell
recombin
viru
pseudotyp
ebov
gp
method
gener
pseudotyp
virus
describ
previou
public
briefli
pseudotyp
viru
contain
supernat
incub
either
serial
dilut
hors
sera
h
addit
preplat
target
cell
cultur
plate
densiti
cellswel
cell
refe
fresh
medium
h
addit
follow
lyse
cell
h
use
cell
lysi
buffer
promega
transfer
lysat
luminomet
plate
luciferas
substrat
promega
ad
plate
rel
luciferas
activ
determin
inhibit
pseudotyp
present
inhibit
highest
serum
dilut
give
reduct
luciferas
activ
regard
neutral
antibodi
titer
ebovegfp
neutral
assay
serial
twofold
dilut
f
antisera
incub
plaqu
form
unit
pfu
ebov
express
egfp
ebovegfp
h
transfer
vero
cell
incub
h
replac
dmem
supplement
fetal
bovin
serum
control
well
contain
pb
instead
f
antisera
sampl
repeat
triplic
plate
fix
phosphat
buffer
formalin
h
infect
score
intens
egfp
use
biotek
synergi
ht
micropl
reader
result
express
percentag
fluoresc
read
control
set
fit
logist
curv
graphpad
statist
analysi
pvalu
rodent
studi
determin
use
logrank
mantelcox
test
calcul
valu
less
consid
statist
signific
vivo
studi
perform
